NR4A1 and cancer: A series of bis-indole-derived analogs (CDIMs) that bind NR4A1 were developed in this laboratory, and initial studies focused primarily on the p-hydroxyphenyl (CDIM8) and p-carboxymethyl phenyl analogs, which acted as NR4A1 antagonists and inactivated NR4A1-regulated pro-oncogenic pathways and genes in cancer cells.